Skip to search formSkip to main contentSkip to account menu

ANA598

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

setrobuvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
2011
2011
THE HEPATITIS C TREATMENT PIPELINE REPORT
BMS-650032 • BOCEPREVIR • CTS-1027 • DANOPREVIR • GS 9256 GS 9451 • IDX 320 • MK-5172 • TELAPREVIR • TMC435350 • VANIPREVIR VX… 
2010
2010
2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
2010
2010
673 ENHANCED IN VITRO ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH OTHER ANTI-HCV AGENTS SUPPORT COMBINATION TREATMENT
2009
2009
1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS
2009
2009
Stomach: Quadruple therapy for Helicobacter pylori eradication
  • J. Gisbert
  • Nature Reviews Gastroenterology &Hepatology
  • 2009
  • Corpus ID: 26855630
The low success rates of standard triple-therapy regimens for eradication of Helicobacter pylori infection have led to… 
2009
2009
90 PRECLINICAL STUDIES OF ANA598 COMBINED WITH OTHER ANTI-HCV AGENTS DEMONSTRATE POTENTIAL OF COMBINATION TREATMENT
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)